

EMLc

ATC codes: **J01AA02**

<b>Indication</b>	Cholera <span>ICD11 code: <b>1A00</b></span>
<b>INN</b>	Doxycycline
<b>Medicine type</b>	Chemical agent
<b>Antibiotic groups</b>	<span>A ACCESS</span>
<b>List type</b>	Core (EML) (EMLc)
<b>Formulations</b>	Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate) (EMLc) ; 50 mg per 5 mL (calcium) (EMLc) Parenteral > General injections > unspecified: 100 mg in vial powder for injection Oral > Solid > dispersible tablet: 100 mg (as monohydrate) (EMLc) Oral > Solid > dosage form: 50 mg (as hyclate) (EMLc) ; 100 mg (as hyclate)
<b>EML status history</b>	First added in 2017 ( <a href="#">TRS 1006</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )
<b>Sex</b>	All
<b>Age</b>	Also recommended for children
<b>Age restriction</b>	Use in children under 8 years of age only for life-threatening infections when no alternatives exist.
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine
<b>Patent information</b>	Patents have expired in most jurisdictions <a href="#">Read more about patents.</a> 
<b>Wikipedia</b>	<a href="#">Doxycycline</a> 
<b>DrugBank</b>	<a href="#">Doxycycline</a> 

### Expert Committee recommendation

In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - replacing the oral liquid formulation of azithromycin (200 mg/5 mL) with powder for oral liquid 200 mg/5 mL on the EML and EMLc. - the addition of a new strength formulation of ciprofloxacin (solid oral dosage form 100 mg (as hydrochloride)) to the EMLc. - the addition of new strength formulations of doxycycline (powder for oral liquid 25 mg/5 mL (monohydrate), oral liquid 50 mg/5 mL (calcium), and dispersible tablet 100 mg (as monohydrate) on the EMLc.

### EML recommendations: Cholera

**First choice**

**Second choice**

azithromycin

ciprofloxacin

doxycycline

[CHILDREN]

azithromycin

ciprofloxacin

doxycycline

